Guide

Is Compounded Tirzepatide Legal in 2026? The Two Pathways, Explained

Patient-specific compounding by a 503A pharmacy under a valid prescription continues. The live question is 503B: the FDA proposed on 30 April 2026 to exclude semaglutide,

The two pathways

What actually changed, and when

1. 2 October 2024 — the FDA declared the tirzepatide shortage resolved. Semaglutide followed in February 2025. That removed the shortage basis for bulk compounding.
2. 5 March 2025 — a federal court denied the Outsourcing Facilities Association's motion to prevent the FDA keeping tirzepatide off the shortage list.
3. 30 April 2026 — the FDA proposed excluding semaglutide, tirzepatide and liraglutide from the 503B Bulks List, on a finding of no clinical need. Notice at 91 FR 23431, published 1 May.
4. 30 July 2026 — the comment period closed, extended from the original late-June deadline after a request for more time.

No final determination has published. Our enforcement page tracks what follows.

What the proposal does not do

It does not address 503A patient-specific compounding, which is the pathway almost every telehealth service uses. It also does not change the position that 503B facilities may compound during a declared shortage.

That distinction is why headlines announcing a ban read as more decisive than the document is.

Legal is not the same as approved

A lawfully compounded preparation is not an FDA-approved finished product. It has not been reviewed for safety, effectiveness or quality before marketing.

The practical consequence is that trial efficacy figures do not transfer. Every number in this field — 22.5% in SURMOUNT-1, 20.2% in SURMOUNT-5 — comes from studies of the approved product in the approved formulation. A preparation containing an added vitamin, a chemical conjugate or a different salt form is outside that. See what is actually in a compounded GLP-1.

Where enforcement has actually landed

The FDA has issued three waves of warning letters in under a year — roughly 80 in September 2025, 30 in February 2026 and 25 in June 2026. Almost all concern advertising rather than compounding itself: whether marketing could leave a consumer believing a compounded product is FDA-approved or equivalent.

Manufacturers have run a parallel campaign. Novo Nordisk sued Hims & Hers on 9 February 2026 for patent infringement and has been reported to have filed more than 130 suits across 40 states.

For a patient, litigation is a supply risk. A provider that settles may stop offering a product with little notice, which is a reason to read refund terms before a prepaid plan.

Two substances that may not be compounded at all

The FDA has published its position that retatrutide and cagrilintide may not be used in compounding. Both circulate in consumer discussion as next-generation options. If a provider offers either as a compounded preparation, that is not a grey area.

The question to ask your provider

Which pharmacy fills the prescription, and is it registered as a 503A pharmacy or a 503B outsourcing facility? The answer determines your exposure to the pending decision.

Almost nobody answers it. Our disclosure register publishes who has and who has not.

Questions readers actually ask